Medpace: Q3 Earnings Snapshot

Medpace Holdings Inc. (MEDP) reported Q3 profit of $137.5M ($4.84 per share) and revenue of $716M. The company expects full-year revenue between $2.84B and $2.86B, according to its earnings release.

Original reporting
Published Oct 21, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medpace: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$MEDPNeutralMed
01

Why it matters

Traders can update models using the reported Q3 profit per share and revenue, then stress-test valuation around the guided full-year revenue range.

02

Market read

The combination of reported Q3 financials and a specific full-year revenue range is a direct catalyst for earnings-model and positioning changes.

03

What to watch

The brief omits cash flow, segment performance, and any commentary on pipeline or contract wins, which often explain post-earnings moves beyond EPS and revenue.

Relevance 8/10Novelty 8/10Timing: reported Wednesday, after-hours/next-session positioning based on the print and guidance

Background

Medpace is an outsourced clinical development services provider; this is a quarterly earnings snapshot with full-year revenue guidance.

Company-level read

Ticker impact

$MEDPNeutralMedium confidence
Context

Medpace reported Q3 profit of $137.5 million, revenue of $716 million, and guided full-year revenue to $2.84B-$2.86B.

Expected impact

Likely modest upside or downside depending on whether the reported EPS and revenue align with Street expectations, with guidance range acting as the main anchor.

Evidence & confidence

The article provides concrete Q3 financials and a full-year revenue outlook, which are direct inputs to earnings-model updates and valuation.

Market effects

Adds incremental datapoints for outsourced clinical development demand and margin trajectory within the clinical services/biopharma services space.

Limited, as the disclosure is company-specific with no broader regional policy or macro linkage.

Low, since the story is a single-company earnings snapshot without cross-border regulatory or trial milestones.

Counterpoint

If the guidance range is broadly in line, the stock reaction may be muted and traders may focus on qualitative factors not included here (margins, backlog, or customer concentration).

Key entities

  • Medpace Holdings Inc.

    Outsourced clinical development services provider reporting Q3 results and full-year revenue guidance.

  • MEDP

    Medpace Holdings Inc. common stock ticker.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.